Josting, A <br/><br/>
Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.  [electronic resource] 

 -  Leukemia & lymphoma  Mar 2000 
 - 115-23 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>1042-8194 
<br/><br/><label>Standard No.: </label>10.3109/10428190009057634  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Carmustine--administration & dosage<br/>Cytarabine--administration & dosage<br/>Dexamethasone--administration & dosage<br/>Etoposide--administration & dosage<br/>Female<br/>Hematopoietic Stem Cell Transplantation<br/>Humans<br/>Lymphoma--drug therapy<br/>Male<br/>Melphalan--administration & dosage<br/>Middle Aged<br/>Remission Induction<br/>Salvage Therapy<br/>Survival Analysis<br/>Transplantation Conditioning<br/>Transplantation, Autologous